|
| Press Releases |
|
 |
|
| Monday, August 1, 2016 |
|
|
Eisai Presents Results of Additional Analysis of Phase III Study of Anticancer Agent Halaven at 14th JSMO Annual Meeting Plenary Session |
| Eisai Co., Ltd. announced today that the results of an additional analysis of a Phase III clinical study (Study 309) of its in-house discovered and developed anticancer agent Halaven in patients with locally advanced, recurrent or metastatic soft tissue sarcoma (liposarcoma or leiomyosarcoma). more info >> |
|
|
Eisai and Mamorio to Jointly Develop "Me-MAMORIO" Tracking Tool to Support People With Dementia Going Out |
| Eisai Co., Ltd. and MAMORIO, Inc. announced today that they have entered into an agreement to collaborate on the development of the MeMAMORIO1 tracking tool to support people with dementia going out. more info >> |
|
| Friday, July 22, 2016 |
|
|
Eisai Receives Positive CHMP Opinion on New Indication for Anticancer Agent Lenvatinib in Combination with Everolimus for Treatment of Advanced Renal Cell Carcinoma |
| Eisai Co., Ltd. announced today that its European regional headquarters Eisai Europe Ltd. has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on anticancer agent lenvatinib mesylate in combination with everolimus. more info >> |
|
| Wednesday, July 20, 2016 |
|
|
U.S. FDA Approves BELVIQ XR, A Once-Daily Formulation of Lorcaserin for Chronic Weight Management |
| Eisai Co., Ltd. has announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for BELVIQ XR, a once-daily formulation of lorcaserin hydrochloride (generic name, U.S. brand name: BELVIQ) for chronic weight management. more info >> |
|
| Thursday, June 30, 2016 |
|
|
Eisai listed for 15th Consecutive Year FTSE4Good Index Series, an Index for Socially Responsible Investment |
| Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 15th consecutive year since its initial inclusion in 2002. more info >> |
|
| Monday, June 20, 2016 |
|
|
AbbVie, Eisai, and EA Pharma Obtain Additional Approval for New Dosing Regimen of Fully Human Anti-TNF Monoclonal Antibody Humira in Patients with Crohn's Disease |
| AbbVie GK, Eisai Co., Ltd., and its subsidiary EA Pharma Co., Ltd. today announced the additional approval for a new dosing regimen of Humira Pre-filled Syringe 40 mg/0.8 mL for Subcutaneous Injection, a fully human anti-TNF monoclonal antibody formulation, in patients with moderate or severe Crohn's disease who become less responsive to treatment with 40 mg every two weeks to double the dose to 80 mg every two weeks. more info >> |
|
| Thursday, June 16, 2016 |
|
|
Eisai Launches New Oral Suspension Formulation for Antiepileptic Drug Fycompa (Perampanel) in the United States |
| Eisai Co., Ltd. announced today that it has launched Fycompa (perampanel) Oral Suspension, a new formulation of its in-house-discovered antiepileptic drug (AED) Fycompa, in the United States. more info >> |
|
| Friday, June 3, 2016 |
|
|
Eisai Inc. Enters Into Collaboration Agreement to Co-Promote Eisai's Anticancer Agent Lenvima in Combination with Evorolimus as Treatment for Advanced Renal Cell Carcinoma in the United States |
| Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has entered into an agreement with Novartis Pharmaceuticals Corporation, a U.S. affiliate of Novartis AG, to collaborate on commercial and medical affairs activities for Eisai's in-house developed novel anticancer agent Lenvima and the anticancer agent everolimus in the United States. more info >> |
|
| Wednesday, June 1, 2016 |
|
|
AbbVie and Eisai Subsidiary EA Pharma Commence Co-promotion of Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA in the Field of Gastrointestinal Disease |
| AbbVie GK, Eisai Co., Ltd. and its subsidiary EA Pharma Co., Ltd., announced that EA Pharma and AbbVie will commence the co-promotion of fully human anti-TNF-alpha monoclonal antibody HUMIRA for indications in the field of gastrointestinal disease (ulcerative colitis, Crohn's disease, intestinal Behcet's disease) as of today. more info >> |
|
| Wednesday, May 25, 2016 |
|
|
Eisai to Launch In-House Developed Antiepileptic Drug Fycompa (Perampanel Hydrate) |
| Eisai Co., Ltd. announced today that it will launch its in-house-discovered antiepileptic drug (AED) Fycompa Tablets 2 mg and 4 mg (perampanel hydrate) as an adjunctive therapy for partial-onset seizures (including secondarily generalized seizures) or primary generalized tonic-clonic seizures in patients with epilepsy showing inadequate response to other AEDs in Japan on May 26, 2016. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan
Nov 28, 2025 23:00 JST
|
|
|
Capital Revo Expands Trader Education Framework Amid Rising 2025 User Engagement 
Nov 28, 2025 22:00 HKT/SGT
|
|
|
Eternal Beauty Holdings Announces First Results Since Listing, Interim Profit for FY2025/2026 Increased 15.3% YoY to RMB 1.3 Million
Nov 28, 2025 20:12 HKT/SGT
|
|
|
JFCR, NEC, and Taiho to Develop Cancer Vaccines Utilizing Whole-Genome Information
Nov 28, 2025 19:41 JST
|
|
|
MHI Publishes "MHI REPORT 2025" and "SUSTAINABILITY DATABOOK 2025"
Nov 28, 2025 19:05 JST
|
|
|
Sharp Wins IAM's "Asia IP Elite 2025", Awarded to Companies with Outstanding Intellectual Property Strategy for The Second Consecutive Year
Nov 28, 2025 18:36 JST
|
|
|
Think Business, Think Hong Kong strengthens Italy-Hong Kong ties and opens new path for Asian collaboration
Nov 28, 2025 17:03 HKT/SGT
|
|
|
Fujitsu builds platform for NSK to create environmental value throughout the product lifecycle of bearing products
Nov 28, 2025 18:01 JST
|
|
|
Fujitsu launches Japan Edition of SAP Fioneer Cloud for Insurance, a next-generation platform supporting core business operations in the Japanese insurance industry
Nov 28, 2025 17:28 JST
|
|
|
Edvantage Group Announces FY2025 Annual Results
Nov 28, 2025 13:00 HKT/SGT
|
|
|
Magnolia Welcomes Tech Pioneer Luc Haldimann as New Board Chairman to Expand Global Growth and AI Strategy
Nov 28, 2025 00:00 HKT/SGT
|
|
|
NEC Launches Sales Support Solution Utilizing Agentic AI
Nov 27, 2025 22:31 JST
|
|
|
Fujitsu and Yamaguchi University develop low-power edge computing technology for near real-time image processing on small satellites
Nov 27, 2025 22:00 JST
|
|
|
Tat Hong Equipment Service Co., Ltd. Announces 2025/26 Interim Results
Nov 27, 2025 18:43 HKT/SGT
|
|
|
PLN Collaborates with Norwegian and Japanese Stakeholders to Advance High-Integrity Cross-Border Carbon Markets at COP30
Nov 27, 2025 18:30 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
